Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis?
African trypanosomiasis has been labelled as a ‘tool-deficient’ disease. This article reflects on the role that Product Development Partnerships (PDPs) have played in delivering new tools and innovations for the control and elimination of the African trypanosomiases. We analysed...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Tropical Medicine and Infectious Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2414-6366/5/1/11 |
_version_ | 1798042183978188800 |
---|---|
author | Emma Michelle Taylor James Smith |
author_facet | Emma Michelle Taylor James Smith |
author_sort | Emma Michelle Taylor |
collection | DOAJ |
description | African trypanosomiasis has been labelled as a ‘tool-deficient’ disease. This article reflects on the role that Product Development Partnerships (PDPs) have played in delivering new tools and innovations for the control and elimination of the African trypanosomiases. We analysed three product development partnerships—DNDi, FIND and GALVmed—that focus on delivering new drugs, diagnostic tests, and animal health innovations, respectively. We interviewed key informants within each of the organisations to understand how they delivered new innovations. While it is too early (and beyond the scope of this article) to assess the role of these three organisations in accelerating the elimination of the African trypanosomiases, all three organisations have been responsible for delivering new innovations for diagnosis and treatment through brokering and incentivising innovation and private sector involvement. It is doubtful that these innovations would have been delivered without them. To varying degrees, all three organisations are evolving towards a greater brokering role, away from only product development, prompted by donors. On balance, PDPs have an important role to play in delivering health innovations, and donors need to reflect on how best to incentivise them to focus and continue to deliver new products. |
first_indexed | 2024-04-11T22:31:56Z |
format | Article |
id | doaj.art-4d6c474f936c47d38f933cf3572781cf |
institution | Directory Open Access Journal |
issn | 2414-6366 |
language | English |
last_indexed | 2024-04-11T22:31:56Z |
publishDate | 2020-01-01 |
publisher | MDPI AG |
record_format | Article |
series | Tropical Medicine and Infectious Disease |
spelling | doaj.art-4d6c474f936c47d38f933cf3572781cf2022-12-22T03:59:21ZengMDPI AGTropical Medicine and Infectious Disease2414-63662020-01-01511110.3390/tropicalmed5010011tropicalmed5010011Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis?Emma Michelle Taylor0James Smith1Department of Social Anthropology, University of Edinburgh, Edinburgh, EH8 9LD, UKCentre of African Studies, University of Edinburgh, Edinburgh, EH8 9LD, UKAfrican trypanosomiasis has been labelled as a ‘tool-deficient’ disease. This article reflects on the role that Product Development Partnerships (PDPs) have played in delivering new tools and innovations for the control and elimination of the African trypanosomiases. We analysed three product development partnerships—DNDi, FIND and GALVmed—that focus on delivering new drugs, diagnostic tests, and animal health innovations, respectively. We interviewed key informants within each of the organisations to understand how they delivered new innovations. While it is too early (and beyond the scope of this article) to assess the role of these three organisations in accelerating the elimination of the African trypanosomiases, all three organisations have been responsible for delivering new innovations for diagnosis and treatment through brokering and incentivising innovation and private sector involvement. It is doubtful that these innovations would have been delivered without them. To varying degrees, all three organisations are evolving towards a greater brokering role, away from only product development, prompted by donors. On balance, PDPs have an important role to play in delivering health innovations, and donors need to reflect on how best to incentivise them to focus and continue to deliver new products.https://www.mdpi.com/2414-6366/5/1/11product development partnershipsresearch and developmentmedical innovationdonor policyafrican trypanosomiasis |
spellingShingle | Emma Michelle Taylor James Smith Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? Tropical Medicine and Infectious Disease product development partnerships research and development medical innovation donor policy african trypanosomiasis |
title | Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? |
title_full | Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? |
title_fullStr | Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? |
title_full_unstemmed | Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? |
title_short | Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? |
title_sort | product development partnerships delivering innovation for the elimination of african trypanosomiasis |
topic | product development partnerships research and development medical innovation donor policy african trypanosomiasis |
url | https://www.mdpi.com/2414-6366/5/1/11 |
work_keys_str_mv | AT emmamichelletaylor productdevelopmentpartnershipsdeliveringinnovationfortheeliminationofafricantrypanosomiasis AT jamessmith productdevelopmentpartnershipsdeliveringinnovationfortheeliminationofafricantrypanosomiasis |